On Demand 2019 Monday General Sessions
This collection covers general sessions from Monday's program. The sessions listed below are included in this package:
- Allergists Can Offer More Than Just Skin Testing
- Urticaria: Are You Itching to Learn More
- Climate Change and Natural Disasters: The Central Role of Allergists
- New Horizons in Chronic Rhinosinusitis
- Managing the Patient with Recurrent Infections
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, the ABAI has designated a maximum of 3 credits as meeting the requirements for MOC Part II Self-Assessment.
Medical professionals who treat patients with allergic and/or immunological conditions:
- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Nurses and advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals
Upon completion of this session, participants should be able to:
- Understand how the FDA approval process determines availability of treatment options
- Address psychosocial aspects of living with allergic conditions with patients during clinical encounters
- Maintain relevance within our specialty through proactive approaches to patient care and education
- Focus on quality measures to help guide optimal patient care
- Define the criteria for chronic and inducible urticaria. Formulate an appropriate diagnostic workup for symptoms suggestive of CIU and inducible urticaria.
- Recognize the various patterns of urticaria and their therapeutic implications, taking into account the potential differential diagnosis.
- Identify components of step-wise management of urticaria following national and international guidelines.
- Be able to discuss various treatment options along with risks versus benefits, including approved biologic therapy, taking into account patient quality-of-life issues.
- Discuss possible roles for allergists in addressing air quality disasters.
- Anticipate medication challenges facing patients during poor air quality.
- Be able to work with public health to develop health care plans for at-risk populations.
- Recognize CRS as a clinical issue and develop an improved knowledge of the etiology and pathogenesis.
- Be able to develop a management plan for a patient with CRS based on new medical and surgical management options.
- Appreciate the involvement of Type 2 inflammation in CRS and the role biologics may play in management.
- Identify factors that affect long-term outcomes in children with PIDD.
- Identify factors that affect long-term outcomes in adults with PIDD.
- Identify and manage two frequent comorbidities: autoimmune cytopenias and malignancies.
Mark M. Ballow, MD, FACAAI
Jonathan A. Bernstein, MD, FACAAI
William K. Dolen, MD, FACAAI
Mary B. Fasano, MD, MSPH, FACAAI
Thomas A. Fleisher, MD, FACAAI
Luz S. Fonacier, MD, FACAAI
Sandra M. Gawchik, DO, FACAAI
Maya Gharfeh, MD, MPH
Alan B. Goldsobel, MD, FACAAI
Joseph Han, MD
Allen Kaplan, MD, FACAAI
Bryan L. Martin, DO, FACAAI
Marcus Maurer, MD
J. Allen Meadows, MD, FACAAI
S. Shahzad Mustafa, MD, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
David B. Peden, MD, FACAAI
Anju T. Peters, MD
Nicholas Rider, DO
Hemant Sharma, MD
Meagan W. Shepherd, MD, FACAAI
Puneet Shroff, MD FACAAI
Jonathan S. Tam, MD, FACAAI
David R. Weldon, MD, FACAAI
- 7.75 AMA PRA Category 1 Credit™
- 7.75 Attendance
- 7.75 CBRN
- 3.00 MOC